此外，公司控股子公司民为生物将具有自主知识产权的MWN105注射液有偿许可给丹麦Sidera公司，截 至12月31日，公司已收到首笔不可撤销的投资款3000万美元。 近日，乐普医疗（300003）发布公告称，预计2025年度归母净利润为8亿元至12亿元，较上年同期的 2.47亿元增长223.97%至385.95%。扣除非经常性损益后的净利润也预计为8亿元至12亿元，相比上年同 期的2.21亿元增长261.29%至441.93%。 公司核心业务心血管植介入营业收入稳中有升，药品板块的零售渠道库存清理基本完成，营业收入实现 双位数增长。 公司在人员优化和组织架构重塑方面已见成效，销售费用与管理费用均有所下降，但受国际外汇市场汇 率变动影响，汇兑损益由上年同期的净收益转为净损失，同时公司拟计提商誉减值准备。 （乐普医疗公告） ...

Group 1 - The company provided an update on its subsidiary Minwei Biopharmaceutical's pipeline development and clinical trials, indicating that MWN109 injection and MWN105 injection are currently in Phase II clinical trials [2] - The oral MWN109 tablet is in the preparatory stage for Phase II clinical trials, while MWX203 injection is in Phase I clinical trials [2] - The company expressed gratitude for investor interest in the progress of its drug development and collaborations with multinational pharmaceutical companies [2]

Core Insights - The report from Guosheng Securities highlights that Lepu Medical's innovative business segment is making significant progress with product approvals and external collaborations, focusing on neuromodulation, innovative drugs, and medical aesthetics as new growth drivers [1] Neuromodulation - The rechargeable implantable deep brain stimulation system has received NMPA approval, marking a key advancement in the neuromodulation sector [1] Innovative Drugs - Lepu Medical has licensed the MWN105 injection to Danish company Sidera for a fee, receiving an initial investment and milestone payments totaling $35 million. Future milestone payments could reach up to $1.01 billion based on clinical development and commercialization sales [1] Medical Aesthetics - The company has received approvals for its Tongyan injection and sodium hyaluronate solution, and has established a strategic partnership with Meituan to enhance product distribution [1] Future Growth Potential - The report suggests that the impact of policies is gradually diminishing, and new businesses like medical aesthetics are in a rapid growth phase, positioning the innovative segment as a key driver for the company's future growth [1]

Core Viewpoint - The article discusses the overseas licensing deal of MWN105 injection by Lepu Medical, highlighting its lower price compared to similar GLP-1 drugs and its potential in the market [1][3]. Company Summary - Lepu Medical's subsidiary, Shanghai Minwei Biotechnology, licensed the overseas rights of MWN105 injection to Danish company Sidera, receiving 9.99% equity in Sidera and a total of $350 million in upfront and milestone payments [1][2]. - The MWN105 injection is a triple receptor agonist (GLP-1/GIP/FGF21) and is the first of its kind globally, with clinical trials for obesity and type 2 diabetes set to begin in China [2][5]. - The licensing agreement includes a combination of equity, milestone payments, and sales royalties, indicating a deep partnership between Minwei and Sidera [2][3]. Industry Summary - The GLP-1 drug market is becoming increasingly competitive, with many Chinese companies actively developing various GLP-1 products, including single, dual, and triple receptor agonists [5]. - The licensing price for MWN105 is significantly lower than similar drugs, setting a new low for domestic products entering overseas markets [5]. - The global market growth for GLP-1 drugs is slowing, with recent adjustments in sales forecasts from major companies like Novo Nordisk, indicating increased competition and high discontinuation rates among patients [5][6].

Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary, Shanghai Minwei Biotech, has granted a paid license for its proprietary MWN105 injection to Danish company Sidera, which will have exclusive rights to develop and commercialize the product outside of Greater China [1] Group 1 - Shanghai Minwei Biotech will receive a 9.99% equity stake in Sidera as part of the licensing agreement [1] - The initial investment and recent milestone payments from Sidera to Shanghai Minwei Biotech will total $35 million [1] - Sidera is obligated to pay up to $1.01 billion in milestone payments based on clinical development and commercialization sales [1] Group 2 - Shanghai Minwei Biotech has the right to receive a tiered sales commission from Sidera based on actual annual net sales, excluding Greater China [1]

Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary, Shanghai Minwei Biotech, has granted a paid license for the MWN105 injection to Danish company Sidera, which will have exclusive rights to develop and commercialize the product outside of Greater China [1] Group 1: Licensing Agreement - Shanghai Minwei Biotech will receive a 9.99% equity stake in Sidera as part of the licensing agreement [1] - The initial investment and recent milestone payments from Sidera to Shanghai Minwei Biotech will total $35 million [1] - Sidera will pay up to $1.01 billion in milestone payments based on clinical development and commercialization sales [1] Group 2: Revenue Sharing - Shanghai Minwei Biotech has the right to receive a tiered sales commission from Sidera based on actual annual net sales, excluding Greater China [1]

Group 1 - The core point of the article is that Lepu Medical has licensed its MWN105 injection to Danish company Sidera, granting Sidera exclusive rights to develop and commercialize the product globally, excluding Greater China [1] - Lepu Medical's subsidiary, Shanghai Minwei Biotech, will receive a 9.99% equity stake in Sidera as part of the licensing deal [1] - The initial investment and recent milestone payments from Sidera to Shanghai Minwei Biotech will total $35 million, with potential milestone payments reaching up to $1.01 billion based on clinical development and commercialization sales [1] Group 2 - The agreement is expected to enhance the global positioning of GLP-1 multi-target drugs, which are gaining traction in the fields of diabetes, obesity, and metabolic diseases [2] - The collaboration aims to expand overseas markets, providing new treatment options for patients while increasing the company's brand influence and international competitiveness [2] - The company emphasizes a dual approach of independent research and open collaboration to accelerate the clinical transformation and market coverage of GLP-1 multi-target drugs, integrating into the global drug innovation ecosystem [2]

Core Insights - Lepu Medical announced a licensing agreement for its MWN105 injection with Denmark's SideraBioAps, granting exclusive rights for development and commercialization outside Greater China [1] - The initial payment and recent milestone payments total $35 million, with SideraBioAps acquiring a 9.99% equity stake in Shanghai Minwei Biotechnology [1] - SideraBioAps is set to pay up to $1.01 billion in milestone payments based on clinical development and commercialization sales [1]

Core Viewpoint - Lepu Medical (300003) announced the licensing of its proprietary MWN105 injection to Denmark's Sidera Bio Aps, granting exclusive rights for development and commercialization outside Greater China [1] Group 1: Licensing Agreement - Lepu Medical's subsidiary, Shanghai Minwei Biotechnology Co., Ltd., will license MWN105 injection to Sidera Bio Aps for a fee [1] - Sidera Bio Aps will receive exclusive rights to develop and commercialize MWN105 injection globally, excluding Greater China [1] Group 2: Financial Aspects - As part of the licensing deal, Shanghai Minwei Biotechnology will acquire a 9.99% equity stake in Sidera Bio Aps [1] - The agreement includes receiving licensing fees from Sidera Bio Aps for the MWN105 injection [1]

Core Viewpoint - Lepu Medical (300003.SZ) has signed an agreement with Denmark's Sidera for the global development and commercialization rights of MWN105 injection, a triple agonist for GLP-1/GIP/FGF21, excluding Greater China [1] Group 1 - Shanghai Minwei Bio will receive a 9.99% equity stake in Sidera as part of the agreement [1] - The company is entitled to receive milestone payments totaling up to $1.01 billion [1] - Shanghai Minwei Bio will also earn sales commissions from Sidera [1] Group 2 - This agreement is expected to enhance the global positioning of the company's GLP-1 multi-target drugs and improve international competitiveness [1] - There are uncertainties associated with drug development and market launch, as well as the milestone payment amounts [1]